ARVN
Price
$6.91Alerts
Change
-$0.01 (-0.14%)
Updated
Nov 11 closing price
Capitalization
419.13M
110 days until earnings call
Intraday BUY SELL Signals
INVA
Price
$18.86Alerts
Change
-$0.22 (-1.15%)
Updated
Nov 11 closing price
Capitalization
1.38B
112 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARVN vs INVA

ARVN vs INVA Comparison Chart in %
View a ticker or compare two or three
VS
ARVN vs. INVA commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARVN is a Hold and INVA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ARVN with price predictions
Nov 10, 2026

ARVN in +7.96% Uptrend, growing for three consecutive days on November 10, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ARVN advanced for three days, in 200 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ARVN's RSI Oscillator exited the oversold zone, 23 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

ARVN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARVN as a result. In 79 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

The Moving Average Convergence Divergence Histogram (MACD) for ARVN turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 38 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

The Aroon Indicator for ARVN entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. ARVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.746) is normal, around the industry mean (3.498). P/E Ratio (21.367) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.733) is also within normal values, averaging (440.869).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for INVA with price predictions
Nov 10, 2026

INVA in downward trend: price dove below 50-day moving average on November 05, 2026

INVA moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend. In 29 of 39 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 74%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INVA as a result. In 43 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 57%.

The Moving Average Convergence Divergence Histogram (MACD) for INVA turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 29 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 64%.

The 10-day moving average for INVA crossed bearishly below the 50-day moving average on November 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +1.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where INVA advanced for three days, in 186 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.

INVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 120 of 204 cases where INVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 28 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. INVA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 81 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.119) is normal, around the industry mean (3.498). P/E Ratio (3.709) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (3.173) is also within normal values, averaging (9.059). Dividend Yield (0.052) settles around the average of (130.981) among similar stocks. P/S Ratio (4.092) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

FUNDAMENTALS RATINGS
ARVN vs INVA: Fundamental Ratings
ARVN
INVA
OUTLOOK RATING
1..100
1758
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
83
Overvalued
PROFIT vs RISK RATING
1..100
10081
SMR RATING
1..100
8328
PRICE GROWTH RATING
1..100
7770
P/E GROWTH RATING
1..100
7196
SEASONALITY SCORE
1..100
2550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INVA's Valuation (83) in the Pharmaceuticals Other industry is in the same range as ARVN (86) in the Biotechnology industry. This means that INVA’s stock grew similarly to ARVN’s over the last 12 months.

INVA's Profit vs Risk Rating (81) in the Pharmaceuticals Other industry is in the same range as ARVN (100) in the Biotechnology industry. This means that INVA’s stock grew similarly to ARVN’s over the last 12 months.

INVA's SMR Rating (28) in the Pharmaceuticals Other industry is somewhat better than the same rating for ARVN (83) in the Biotechnology industry. This means that INVA’s stock grew somewhat faster than ARVN’s over the last 12 months.

INVA's Price Growth Rating (70) in the Pharmaceuticals Other industry is in the same range as ARVN (77) in the Biotechnology industry. This means that INVA’s stock grew similarly to ARVN’s over the last 12 months.

ARVN's P/E Growth Rating (71) in the Biotechnology industry is in the same range as INVA (96) in the Pharmaceuticals Other industry. This means that ARVN’s stock grew similarly to INVA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARVNINVA
RSI
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
58%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
57%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
64%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
60%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
57%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 14 days ago
63%
Declines
ODDS (%)
Bearish Trend 6 days ago
81%
Bearish Trend 3 days ago
64%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
71%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
59%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (ARVN: $6.92 vs. INVA: $19.08)
Brand notoriety: ARVN and INVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARVN: 74% vs. INVA: 90%
Market capitalization -- ARVN: $419.13M vs. INVA: $1.38B
ARVN [@Biotechnology] is valued at $419.13M. INVA’s [@Biotechnology] market capitalization is $1.38B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARVN’s FA Score shows that 0 FA rating(s) are green while INVA’s FA Score has 1 green FA rating(s).

  • ARVN’s FA Score: 0 green, 5 red.
  • INVA’s FA Score: 1 green, 4 red.
According to our system of comparison, INVA is a better buy in the long-term than ARVN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARVN’s TA Score shows that 4 TA indicator(s) are bullish while INVA’s TA Score has 5 bullish TA indicator(s).

  • ARVN’s TA Score: 4 bullish, 4 bearish.
  • INVA’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both ARVN and INVA are a good buy in the short-term.

Price Growth

ARVN (@Biotechnology) experienced а -2.40% price change this week, while INVA (@Biotechnology) price change was -8.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

ARVN is expected to report earnings on Mar 01, 2027.

INVA is expected to report earnings on Mar 03, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ARVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARVN has been loosely correlated with OLMA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ARVN jumps, then OLMA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARVN
1D Price
Change %
ARVN100%
+2.37%
OLMA - ARVN
48%
Loosely correlated
-1.22%
BCYC - ARVN
47%
Loosely correlated
-2.12%
AXON - ARVN
46%
Loosely correlated
-0.21%
VCYT - ARVN
46%
Loosely correlated
-7.18%
STOK - ARVN
46%
Loosely correlated
-1.80%
More

INVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, INVA has been loosely correlated with ARQT. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if INVA jumps, then ARQT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INVA
1D Price
Change %
INVA100%
+0.42%
ARQT - INVA
38%
Loosely correlated
+4.52%
ARVN - INVA
35%
Loosely correlated
+2.37%
DTIL - INVA
34%
Loosely correlated
-1.86%
LGND - INVA
31%
Poorly correlated
+0.00%
ATRA - INVA
31%
Poorly correlated
-0.98%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ET19.430.34
+1.78%
Energy Transfer LP
PPIH29.53-0.12
-0.40%
Perma-Pipe International Holdings
BB9.14-0.08
-0.87%
BlackBerry Limited
SIBN25.10-0.50
-1.95%
SI-BONE
EOCN2.50-0.09
-3.47%
Eocene Ltd.